The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Activity and safety of bortezomib in multiple myeloma patients with advanced renal failure: a multicenter retrospective study
Open accessAbstract
Patients with multiple myeloma (MM) frequently present with concomitant renal dysfunction, and those requiring dialysis have particularly poor outcomes. Bortezomib is a reversible proteasome inhibitor with significant activity in MM. This retrospective case analysis evaluated the feasibility and activity of bortezomib-based therapy in MM patients (n = 24) requiring dialysis support for advanced renal failure. All but 1 patient were undergoing dialysis at the time of therapy. Patients received bortezomib alone or bortezomib-based combination therapy. Among 20 patients with available response data, overall response rate (complete response [CR] + partial response) was 75%, with 30% CR + near CR. One patient was spared dialysis, and 3 other patients became independent of dialysis following bortezomib-based treatment. These encouraging results suggest that bortezomib or bortezomib-based regimens can be used in MM patients requiring dialysis, with manageable toxicities. Further studies will more formally evaluate the impact of bortezomib-based regimens in this patient population.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Phase 2 Study of Bortezomib in Relapsed, Refractory Myeloma
Richardson, P. G., Barlogie, B., Berenson, J., Singhal, S., Jagannath, S., Irwin, D., Rajkumar, S. V., Srkalovic, G., Alsina, M., Alexanian, R., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030288 · Cited by 2,632
Self-citationBortezomib or High-Dose Dexamethasone for Relapsed Multiple Myeloma
Richardson, P. G., Sonneveld, P., Schuster, M. W., Irwin, D., Stadtmauer, E. A., Facon, T., Harousseau, J.-L., Ben-Yehuda, D., Lonial, S., Goldschmidt, H., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043445 · Cited by 2,491
Self-citationReview of 1027 Patients With Newly Diagnosed Multiple Myeloma
Kyle, R. A., Gertz, M. A., Witzig, T. E., Lust, J. A., Lacy, M. Q., Dispenzieri, A., Fonseca, R., Rajkumar, S. V., Offord, J. R., Larson, D. R., et al. (2003) · Mayo Clinic Proceedings · doi:10.4065/78.1.21 · Cited by 2,447
BladÉ, J., Samson, D., Reece, D., Apperley, J., BJÖrkstrand, B., Gahrton, G., Gertz, M., Giralt, S., Jagannath, S., Vesole, D., et al. (1998) · British Journal of Haematology · doi:10.1046/j.1365-2141.1998.00930.x · Cited by 1,519
A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma
Jagannath, S., Barlogie, B., Berenson, J., Siegel, D., Irwin, D., Richardson, P. G., Niesvizky, R., Alexanian, R., Limentani, S. A., Alsina, M., et al. (2004) · British Journal of Haematology · doi:10.1111/j.1365-2141.2004.05188.x · Cited by 740
Self-citationAugustson, B. M., Begum, G., Dunn, J. A., Barth, N. J., Davies, F., Morgan, G., Behrens, J., Smith, A., Child, J. A., & Drayson, M. T. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.2086 · Cited by 488
Bladé, J., Fernández-Llama, P., Bosch, F., Montolíu, J., Lens, X. M., Montoto, S., Cases, A., Darnell, A., Rozman, C., & Montserrat, E. (1998) · Archives of Internal Medicine · doi:10.1001/archinte.158.17.1889 · Cited by 383
Renal failure in multiple myeloma: reversibility and impact on the prognosis
Knudsen, L. M., Hjorth, M., Hippe, E., & Nordic Myeloma Study Group (2000) · European Journal of Haematology · doi:10.1034/j.1600-0609.2000.90221.x · Cited by 380
Orlowski, R. Z., Voorhees, P. M., Garcia, R. A., Hall, M. D., Kudrik, F. J., Allred, T., Johri, A. R., Jones, P. E., Ivanova, A., Van Deventer, H. W., et al. (2005) · Blood · doi:10.1182/blood-2004-07-2911 · Cited by 319
Results of autologous stem cell transplant in multiple myeloma patients with renal failure
Badros, A., Barlogie, B., Siegel, E., Roberts, J., Langmaid, C., Zangari, M., Desikan, R., Shaver, M. J., Fassas, A., McConnell, S., et al. (2001) · British Journal of Haematology · doi:10.1046/j.1365-2141.2001.03033.x · Cited by 306
Self-citation
Cited by
Raab, M. S., Podar, K., Breitkreutz, I., Richardson, P. G., & Anderson, K. C. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60221-x · Cited by 697
Self-citationKumar, S. K., Mikhael, J. R., Buadi, F. K., Dingli, D., Dispenzieri, A., Fonseca, R., Gertz, M. A., Greipp, P. R., Hayman, S. R., Kyle, R. A., et al. (2009) · Mayo Clinic Proceedings · doi:10.4065/mcp.2009.0603 · Cited by 628
Mikhael, J. R., Dingli, D., Roy, V., Reeder, C. B., Buadi, F. K., Hayman, S. R., Dispenzieri, A., Fonseca, R., Sher, T., Kyle, R. A., et al. (2013) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2013.01.019 · Cited by 500
Self-citationDimopoulos, M. A., Terpos, E., Chanan-Khan, A., Leung, N., Ludwig, H., Jagannath, S., Niesvizky, R., Giralt, S., Fermand, J.-P., Bladé, J., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.30.8791 · Cited by 414
Self-citationHow I treat monoclonal gammopathy of renal significance (MGRS)
Fermand, J.-P., Bridoux, F., Kyle, R. A., Kastritis, E., Weiss, B. M., Cook, M. A., Drayson, M. T., Dispenzieri, A., & Leung, N. (2013) · Blood · doi:10.1182/blood-2013-05-495929 · Cited by 326
Metadata
- Authors
- Chanan-Khan, A. A., Kaufman, J. L., Mehta, J., Richardson, P. G., Miller, K. C., Lonial, S., Munshi, N. C., Schlossman, R., Tariman, J., & Singhal, S.
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2006-11-30
- Volume
- 109
- Issue
- 6
- Pages
- 2604-2606
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- OpenAlex
- W2095328443
- Cited by
- 256
- References
- 18
- FWCI
- 12.97
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Activity and safety of bortezomib in multiple myeloma patients with advanced renal failure: a multicenter retrospective study. https://app.cochat.ai/papers/10.1182/blood-2006-09-046409
- The paper
- Chanan-Khan, A. A., Kaufman, J. L., Mehta, J., Richardson, P. G., Miller, K. C., Lonial, S., Munshi, N. C., Schlossman, R., Tariman, J., & Singhal, S. (2007). Activity and safety of bortezomib in multiple myeloma patients with advanced renal failure: a multicenter retrospective study. Blood. https://doi.org/10.1182/blood-2006-09-046409
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.